BioPharma Clinical Trials

Nectin Therapeutics Expands Clinical Trial to Israel, Progresses Swiftly

Nectin Therapeutics Ltd., (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology t...

 December 27, 2023 | News

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria. Drug resistance of anti...

 December 27, 2023 | News

Asieris' APL-2301 Approved for Phase I Trials in Australia for Acinetobacter baumannii Infection

The planned clinical trial in Australia will be the first-in-human Phase I trial for APL-2301. It aims to evaluate the safety, tolerability, phar...

 December 26, 2023 | News

Oncoshot Collaborates with Zhejiang Ablaze for Data-Driven Drug Development in China

This collaboration brings together complementary strengths - Oncoshot's capabilities in data analysis and insights generation with Ablaze's recent expansio...

 December 26, 2023 | News

TransThera Completes First Patient Dosing in US for Global Phase 3 Trial of Tinengotinib in FGFRi Relapsed/Refractory Cholangiocarcinoma

This study is a Phase 3, randomized, controlled, global multicenter study to evaluate the efficacy and safety of oral tinengotinib versus physician's choic...

 December 22, 2023 | News

Everest Medicines' Partner Calliditas Announces Nefecon® as Sole FDA-Approved Treatment for Slowing IgA Nephropathy Kidney Decline

The FDA approval is for adults with primary IgAN who are at risk for disease progression, irrespective of proteinuria levels. Nefecon® is now a...

 December 21, 2023 | News

BioCity Doses First Patient in Phase Ib/II Trial of BC3402 Anti-TIM-3 mAb with IMFINZI for Advanced Hepatocellular Carcinoma

The study is being conducted at Zhongshan Hospital with Prof. Jia Fan as the principal investigator. Dr. Fan is a world-renowned liver cancer sur...

 December 21, 2023 | News

NMPA Accepts Mabwell's 8MW0511 Injection New Drug Application

8MW0511, a Class 1 therapeutic biological product, is a new generation of long-acting G-CSF (modified cytokine with high activity) with independent intelle...

 December 20, 2023 | News

Australian Neuren Phase 2 Trial Reveals Significant Improvements in Phelan-McDermid Syndrome

Highlights:  Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures   Improvements were con...

 December 19, 2023 | News

Advancing Lung Cancer Treatment: Insights from Professor Benjamin Solomon on the ALINA Study and the Future of ALK-Positive NSCLC

In an exclusive BioPharma APAC interview, Professor Benjamin Solomon, a distinguished Medical Oncologist at the Peter MacCallum Cancer Centre, Australia, a...

 December 18, 2023 | News

InnoCare's TYK2 Inhibitor ICP-332 Meets Phase II Endpoint in Atomic Dermatitis Study

ICP-332 in AD patients treated for 4 weeks demonstrated excellent efficacy and safety profile. ICP-332 achieved multiple efficacy endpoints including Eczem...

 December 18, 2023 | News

GC Biopharma's ALYGLO™ 10% Liquid FDA Approved for Adult Primary Immunodeficiency.

The ALYGLO pivotal phase 3 clinical study followed FDA guidance for the treatment of patients with PI. The clinical trial (NCT02783482) GC5107B was a prosp...

 December 18, 2023 | News

Fosun Pharma's Antimalarial Drug Trial Gets 500 Million Yen Boost from GHIT Fund for Global Accessibility Initiative

The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced that it will invest approximately US$3.3 million (approximate...

 December 15, 2023 | News

Atmo Biosciences achieves patient recruitment target for dysmotility pivotal clinical study

Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome fu...

 December 14, 2023 | News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in